EXPRESSION OF THE SART3 TUMOR REJECTION ANTIGEN IN RENAL CELL CARCINOMA

This publication has 26 references indexed in Scilit:

• Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage
  The Journal of Experimental Medicine, 1998
• Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor
  Immunity, 1997
• Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes
  International Journal of Cancer, 1996
• Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
  The Journal of Experimental Medicine, 1996
• Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
  Proceedings of the National Academy of Sciences, 1994
• Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
  Proceedings of the National Academy of Sciences, 1994
• Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer
  JNCI Journal of the National Cancer Institute, 1993
• Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
  Journal of Clinical Oncology, 1992
• A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
  Science, 1991
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987